ClinicalTrials.gg
CompletedNCT02186509Updated Apr 30, 2025Results posted

Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas

A Phase 1 interventional study of Hyperfractionated radiation therapy and Stereotactic radiosurgery in Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma and Adult Anaplastic Oligodendroglioma, sponsored by Sidney Kimmel Cancer Center at Thomas Jefferson University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-30.

Primary conditionGlioblastomaRegistry: AstrocytomaReclassifiedWhy we changed it
Registry
Astrocytoma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Glioblastoma
Why
  1. The study's listed conditions name Glioblastoma, a narrower term within Astrocytoma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sidney Kimmel Cancer Center at Thomas Jefferson University · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,302 studies in Glioblastoma with a site in United States — 194 open to participants now, 324 under way, 16 of them phase 3. Glioblastoma · United States.

Enrollment
834th of 1,155
17 · median 33
Started
2015
with 42 others
Phase 1
481 of 1,302
70 open now
Registered
646th of 1,302
by date

Among the 1,302 studies in Glioblastoma with a site in United States, this one is the 834th largest by enrollment of the 1,155 interventional ones that give a count, is one of 43 that started in 2015, is one of 481 in phase 1, and was the 646th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

194 of the 1,302 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:

189 more — sign in →

All 194 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,302 studies in Glioblastoma with a site in United States, or all of them as a file.
02

Study summary

This phase I trial studies the side effects and best dose of alisertib when combined with fractionated stereotactic radiosurgery in treating patients with high-grade gliomas that have returned after previous treatment with radiation therapy (recurrent). Alisertib may stop the growth of tumor cells by blocking an enzyme needed for the cells to divide. Radiation therapy uses high energy x rays to kill tumor cells. Stereotactic radiosurgery uses special positioning equipment to send a single high dose of radiation directly to the tumor and cause less damage to normal tissue. Delivering stereotactic radiosurgery over multiple doses (fractionation) may cause more damage to tumor tissue than normal tissue while maintaining the advantage of its accuracy.

Read the detailed description

PRIMARY OBJECTIVES:

I. Evaluate the safety and tolerability of the study treatment. II. To determine the maximum tolerated dose (MTD) of daily oral alisertib when combined with fractionated stereotactic radiation treatment for recurrent high grade glioma.

SECONDARY OBJECTIVES:

I. To estimate 6 month progression free survival rate. II. To estimate the median time to progression. III. To estimate overall survival. IV. To estimate the impact on quality of life (QoL).

OUTLINE: This is a dose-escalation study of alisertib.

CONCURRENT PHASE: Patients undergo fractionated stereotactic radiosurgery once daily (QD) every weekday for 10 days and receive alisertib orally (PO) twice daily (BID) concurrently with radiation therapy for 10 days.

MAINTENANCE PHASE: Patients receive alisertib PO BID on days 1-7. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 1 year and then every 4-6 months thereafter.

03

Conditions studied

  • Adult Anaplastic Astrocytoma
  • Adult Anaplastic Ependymoma
  • Adult Anaplastic Oligodendroglioma
  • Adult Brain Stem Glioma
  • Adult Diffuse Astrocytoma
  • Adult Giant Cell Glioblastoma
  • Adult Glioblastoma
  • Adult Gliosarcoma
  • Adult Mixed Glioma
  • Adult Oligodendroglioma
  • Adult Pilocytic Astrocytoma
  • Adult Pineal Gland Astrocytoma
  • Adult Subependymal Giant Cell Astrocytoma
  • Recurrent Adult Brain Tumor
04

In context

Glioblastoma Reclassified

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

This study's enrollment of 17 is below the median of 36 across 1,756 interventional studies indexed under Glioblastoma.

Browse Glioblastoma studies →

Lead sponsor

Sidney Kimmel Cancer Center at Thomas Jefferson University is the lead sponsor of 120 studies on the registry; none are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 7 (30%) have results posted.

Compared within Glioblastoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Astrocytoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must have a previously or cytologically confirmed high grade glioma (astrocytic or oligodendroglial supratentorial tumors grade 3 or 4) that has been previously treated with fractionated radiation therapy and now shows evidence of recurrence.
  2. Patients must have recovered from the toxic effects of prior therapy.
  3. Patients must have recovered from the effects of surgery. There must be a minimum of 21 days from the day of surgery to the day of protocol treatment. For core or needle , a minimum of 7 days must have elapsed prior to the day of protocol treatment.
  4. Prior treatment with cytotoxic and biological agents is permissible. There should be at least a 2-week break between prior treatment and the protocol treatment.
  5. Prior treatment with fractionated radiation therapy (up to 60Gy) is an eligibility criterion, however there should not have been a second course of fractionated radiotherapy to the supratentorial area.
  6. One prior single fraction radiosurgical procedure within the treatment field is acceptable if V12\<5 cc (V12 is the volume of normal brain (outside GTV) receiving 12 or more Gy). Additional radiosurgical procedures outside of the treatment area are acceptable.
  7. Subject must be able to take oral medication and to maintain a fast, is required for 2 hours before and 1 hour after MLN8237 administration.
  8. > 1500/mm³, > 100,000/mm³, > 9 g/dL. Values must be obtained without need for myeloid growth factor or platelet transfusion support within 14 days of registration. However, erythrocyte growth factor is allowed as per published ASCO guidelines.
  9. Total ≤ , (AST) and SGPT (ALT)\< 1.5 x ULN, within 14 days of registration.
  10. Adequate renal function as defined by: calculated must be ≥40 mL/minute (Cockcroft-Gault), within 14 days of registration.
  11. Age >18 years.
  12. performance status \<2 (see Appendix I).
  13. of greater than 2 months.
  14. Women of must have a negative β-HCG pregnancy test documented within 7 days prior to registration.
  15. Women of child-bearing potential and men must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry and for 4 months after last dose.
  16. Ability to understand and the willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  1. Known history of uncontrolled sleep apnea syndrome and other conditions that could result in excessive daytime sleepiness such as severe requiring supplemental oxygen.
  2. Systemic infection requiring IV antibiotic therapy within 14 days preceding the first dose of study drug, or other severe infection.
  3. Myocardial infarction within 6 months prior to enrollment, (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any abnormality at Screening has to be documented by the investigator as not medically relevant.
  4. Female subject is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for or surgically sterilized women.
  5. Patient has received other drugs within 14 days before enrollment
  6. Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
  7. Other severe acute or chronic medical or psychiatric condition, including uncontrolled diabetes, malabsorption, resection of the pancreas or upper small bowel, requirement for pancreatic enzymes, any condition that would modify small bowel absorption of oral medications, or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for enrollment in this study.
  8. Treatment with enzyme inducers, such as the enzyme-inducing antiepileptic drugs phenytoin, carbamazepine or phenobarbital, or rifampin, rifabutin, rifapentine or St. John's wort within 14 days prior to the first dose of MLN8237 and during the study.
  9. Known history of (HIV) infection, , or . Testing is not required in the absence of clinical findings or suspicion.
  10. Patients have a history of any other from which the patient has been disease-free for less than 2 years, with the exception of adequately treated basal or squamous cell carcinoma of skin, superficial bladder cancer or carcinoma in situ of cervix, AJCC (version 7.0) stage 0 or I breast cancer, AJCC (version 7.0) stage I, or II prostate cancer.
  11. Radiation therapy to more than 25% of the bone marrow. Whole pelvic radiation is considered to be over 25%.
  12. Patients who cannot swallow whole tablets (i.e. medication tablets)
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Alisertib, fractionated stereotactic radiosurgery

    CONCURRENT PHASE: Patients undergo fractionated stereotactic radiosurgery QD every weekday for 10 days and receive alisertib PO BID concurrently with radiation therapy for 10 days. MAINTENANCE PHASE: Patients receive alisertib PO BID on days 1-7. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.

    Radiation: Hyperfractionated radiation therapy · Radiation: Stereotactic radiosurgery · Drug: Alisertib · Procedure: Quality-of-life assessment

Interventions

  • RadiationHyperfractionated radiation therapy

    Undergo hyperfractionated radiation therapy

  • RadiationStereotactic radiosurgery

    Undergo stereotactic radiosurgery

  • Given PO

    Also known as: MLN8237

  • ProcedureQuality-of-life assessment

    Ancillary studies

07

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) of Alisertib

    Defined as the dose at which \>= 2 patients experience dose-limiting toxicity, graded in severity according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0

    Time frame: Up to 30 days after completion of radiation therapy

Secondary outcomes

  1. Number of Participants With Complete or Partial Response

    95% confidence intervals will be computed. Response was defined by the Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Work Group (RANO)

    Time frame: Up to 5 years

  2. Number of Participants With Progression Free Survival at 6 Months

    Estimated through the Kaplan-Meier method.

    Time frame: At 6 months

  3. Number of Participants With Overall Survival at 6 Months

    Estimated through the Kaplan-Meier method.

    Time frame: At 6 months

08

Results

Posted Sep 9, 2019

Participant flow

Participant flow — Overall Study
MilestoneAlisertib, Fractionated Stereotactic Radiosurgery
Started17
Completed17
Not completed0

Outcome measures

PrimaryMaximum Tolerated Dose (MTD) of Alisertib

Defined as the dose at which \>= 2 patients experience dose-limiting toxicity, graded in severity according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0

Time frame:
Up to 30 days after completion of radiation therapy
Reported as:
Number · mg dose of Alisertib
Maximum Tolerated Dose (MTD) of Alisertib
mg dose of AlisertibAlisertib, Fractionated Stereotactic Radiosurgery
Maximum Tolerated Dose (MTD) of Alisertib50
SecondaryNumber of Participants With Complete or Partial Response

95% confidence intervals will be computed. Response was defined by the Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Work Group (RANO)

Time frame:
Up to 5 years
Reported as:
Count of participants · Participants
Number of Participants With Complete or Partial Response
ParticipantsAlisertib, Fractionated Stereotactic Radiosurgery
Number of Participants With Complete or Partial Response0
SecondaryNumber of Participants With Progression Free Survival at 6 Months

Estimated through the Kaplan-Meier method.

Time frame:
At 6 months
Reported as:
Count of participants · Participants
Number of Participants With Progression Free Survival at 6 Months
ParticipantsAlisertib, Fractionated Stereotactic Radiosurgery
Number of Participants With Progression Free Survival at 6 Months6
SecondaryNumber of Participants With Overall Survival at 6 Months

Estimated through the Kaplan-Meier method.

Time frame:
At 6 months
Reported as:
Count of participants · Participants
Number of Participants With Overall Survival at 6 Months
ParticipantsAlisertib, Fractionated Stereotactic Radiosurgery
Number of Participants With Overall Survival at 6 Months15

Adverse events

Collected over 18 months from baseline. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alisertib, Fractionated Stereotactic Radiosurgery15/17 (88.2%)6/17 (35.3%)17/17 (100%)
Most frequent serious events
Most frequent serious events
EventAlisertib, Fractionated Stereotactic Radiosurgery
LeukopeniaBlood and lymphatic system disorders2/17
NeutropeniaBlood and lymphatic system disorders2/17
LymphopeniaBlood and lymphatic system disorders1/17
HeadacheNervous system disorders1/17
Most frequent other events
Showing 10 of 20
Most frequent other events
EventAlisertib, Fractionated Stereotactic Radiosurgery
FatigueGeneral disorders13/17
LymphopeniaBlood and lymphatic system disorders7/17
AnemiaBlood and lymphatic system disorders6/17
LeukopeniaBlood and lymphatic system disorders5/17
HpocalcemiaMetabolism and nutrition disorders5/17
HyperlipidemiaBlood and lymphatic system disorders4/17
Gait DisturbanceNervous system disorders4/17
Muscle WeaknessMusculoskeletal and connective tissue disorders4/17
HyperbilirubinemiaHepatobiliary disorders3/17
HeadacheNervous system disorders3/17

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Alisertib, Fractionated Stereotactic Radiosurgery
<=18 years0
Between 18 and 65 years12
>=65 years5
Sex: Female, Male
Sex: Female, Male(Participants)Alisertib, Fractionated Stereotactic Radiosurgery
Female5
Male12
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Alisertib, Fractionated Stereotactic Radiosurgery
Hispanic or Latino2
Not Hispanic or Latino15
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Alisertib, Fractionated Stereotactic Radiosurgery
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White17
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Alisertib, Fractionated Stereotactic Radiosurgery
United States17
09

Study locations

1 site
  • Sidney Kimmel Cancer Center at Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
10

References and documents

Publications

  • Song A, Andrews DW, Werner-Wasik M, Kim L, Glass J, Bar-Ad V, Evans JJ, Farrell CJ, Judy KD, Daskalakis C, Zhan T, Shi W. Phase I trial of alisertib with concurrent fractionated stereotactic re-irradiation for recurrent high grade gliomas. Radiother Oncol. 2019 Mar;132:135-141. doi: 10.1016/j.radonc.2018.12.019. Epub 2019 Jan 4. PubMed 30825962 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2015 to primary completion in Mar 2017, 26 months.

Results were first posted in Sep 2019, 2 years 5 months after primary completion.

Of 239 non-industry phase 1 interventional studies under Glioblastoma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 76. This study's 26 months is below that.

Counting every sponsor, half of 321 studies reached it within 44 months; a quarter within 29 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2014
First posted
Jul 10, 2014
StartActual
Jan 30, 2015
Primary completionActual
Mar 31, 2017
CompletionActual
Dec 31, 2018
Results first posted
Sep 9, 2019
Last update
Apr 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02186509
Responsible party
Sponsor
First posted
Jul 10, 2014
Start date
Jan 30, 2015
Primary completion
Mar 31, 2017
Completion
Dec 31, 2018
Results posted
Sep 9, 2019
Last update
Apr 30, 2025

Study contacts

Wenyin Shi, MD, PhD
principal investigator · Thomas Jefferson University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MLN 8237

Start the discussion